# EDGAR Filing Document

**Accession Number:** 0001106644
**File Stem:** 0001213900-25-120129
**Filing Date:** 2025-12
**Character Count:** 6123
**Document Hash:** 7ce29ca15e6c033e6d0162b2141a7bb8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-120129.hdr.sgml**: 20251210

**ACCESSION NUMBER**: 0001213900-25-120129

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20251204

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Unregistered Sales of Equity Securities

**FILED AS OF DATE**: 20251210

**DATE AS OF CHANGE**: 20251210

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CHINA PHARMA HOLDINGS, INC.
- **CENTRAL INDEX KEY:** 0001106644
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 731564807
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-34471
- **FILM NUMBER:** 251562532

**BUSINESS ADDRESS:**
- **STREET 1:** 2ND FLOOR, NO. 17, JINPAN ROAD
- **STREET 2:** HAIKOU
- **CITY:** HAINAN PROVINCE
- **STATE:** F4
- **ZIP:** 570216
- **BUSINESS PHONE:** 8689866811730

**MAIL ADDRESS:**
- **STREET 1:** 2ND FLOOR, NO. 17, JINPAN ROAD
- **STREET 2:** HAIKOU
- **CITY:** HAINAN PROVINCE
- **STATE:** F4
- **ZIP:** 570216

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TS ELECTRONICS INC
- **DATE OF NAME CHANGE:** 20030818

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SOFTSTONE INC
- **DATE OF NAME CHANGE:** 20030128

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SOFTSTONE INC /DE/
- **DATE OF NAME CHANGE:** 20010808

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **December 4, 2025**

**CHINA PHARMA HOLDINGS, INC.**

(Exact name of Registrant as specified in charter)

---

| | | |
|:---|:---|:---|
| **Nevada** | **001-34471** | **73-1564807** |
| (State or other jurisdiction | (Commission File No.) | (IRS Employer |
| of Incorporation) |  | Identification No.) |

---

**<u>Second Floor, No. 17, Jinpan Road</u>**

**<u>Haikou, Hainan Province, China 570216</u>**

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **<u>+86 898-6681-1730 (China)</u>**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)

☐ Soliciting material pursuant to Rule14a-12 under the Exchange Act (17CFR240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock | CPHI | NYSE American |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

| | |
|:---|:---|
| **Item 1.01** | **Entry into a Material Definitive Agreement.** |

---

On December 4, 2025, Hainan Helpson Medical & Biotechnology Co., Ltd ("**Helpson**"), a wholly owned subsidiary of China Pharma Holdings, Inc. (the "**Company**"), entered into a Technology Transfer Agreement (the "**Agreement**") with Lijie Tang (the "**Transferor**"). The Transferor owns an invention patent of a Captopril microcapsule and Method for Its Preparation (the "**Invention Patent**"). Pursuant to the Agreement, the Transferor will transfer the ownership of the Invention Patent to Helpson. The Transferor or its designated third party shall provide relevant technical services, which include but are not limited to product research and development, writing of registration materials, registration application and other technical services.

The transfer price as contemplated by the Agreement is $6.3 million, which will be paid in the form of common stock of the Company, par value $0.001 per share (the "**Common Stock**"), at $1.80 per share.

---

| | |
|:---|:---|
| **Item 3.02** | **Unregistered Sales of Equity Securities.** |

---

The information contained in Item 1.01 of this Current Report on Form 8-K in relation to the issuance of the Company's securities mentioned above is incorporated herein by reference. The Company is to issue an aggregate of 3,500,000 restricted shares of Common Stock in connection with the technology transfer.

The Company's securities mentioned above, if and when issued, will not be registered under the Securities Act as amended (the "**Securities Act**"), or the securities laws of any state, and are being offered and issued in reliance on the exemption from registration under the Securities Act afforded by Regulation S promulgated thereunder for the issuance of the shares to the person who is a non-U.S. person as the securities are being issued to the person through an offshore transaction which was negotiated and consummated outside the United States.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 10, 2025

---

| | |
|:---|:---|
| **CHINA PHARMA HOLDINGS, INC.** | **CHINA PHARMA HOLDINGS, INC.** |
| By: | /s/ Zhilin Li |
|  | Name: Zhilin Li<br> Title: President and Chief Executive Officer |

---